#OP0224 Estimating clinical meaningful threshold for disease activity and improvement in composite measures of disease activity in 139 PsA patients over 3 clinical visits. Usefulness for clinics and further testing in different settings warranted @RheumNow #EULAR2021 https://t.co/mwHJwIhRVE

#OP0228 Phase 3 RCT on Risankizumab - KEEPsAKE 2 -PsA with 49% prior bDMARD 95% prior csDMARD: week 24 results PE: ACR20 51% active vs 26% on PLC PASI90: 55% active vs. 10% PLC #EULAR2021 @RheumNow https://t.co/UkZLcXTNnq

Several domains of disease in #PsA need to be considered. Composite scores have the benefit of providing a summary. What is your favourite composite score for PsA in your clinical practice? #EULAR2021 @RheumNow

The COSMOS study results showed that GUS 100 mg Q8W showed ⬆️ ACR20 vs PBO at W24 in TNFi IR PsA pts who had tried 1-2 prior TNFi. What MOA do you choose after 1st TNFi IR in your PsA pts? Abstract #OP0230 #EULAR2021 @RheumNow https://t.co/Jb7GqkHtYz

• https://ard.bmj.com/content/80/Suppl_1/140.full

⭐️Deucravacitnib = oral TYK2i w/ downstream inhibitory effects on IL23, IL12 & type I IFN pathways ⭐️Recent studies (POETYK PSO-1/2) show that it outperforms Otezla per PASI75 ⭐️OP0227 shows it is also efficacious for active PsA vs PBO w/ no serious AEs #EULAR2021 @Rheumnow https://t.co/qA1NsLzQsF

RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, and Janssen. All content chosen by RheumNow and its faculty.